AstraZeneca receives boost with Farxiga cardiovascular dataThe FT at the weekend said AstraZeneca's Farxiga (dapagliflozin) reduces the chances of diabetic patients being hospitalised with heart failure, a condition associated with type 2 diabetes. (APMHE 60534)
Bayer to challenge weedkiller rulingsThe FT on Tuesday said Bayer reported flat earnings in the third quarter. In relation to the ongoing litigation in the U.S. regarding the safety of Monsanto's popular glyphosate herbicide, Bayer said 9,300 plaintiffs had taken legal action against it at the end of October. (APMHE 60563)
Obesity pillAn obesity pill that expands into a gel almost 100 times its original size after being swallowed has moved one step closer to approval, The Telegraph reported on Tuesday.
Samsung BioLogics violated accounting rules - watchdogSamsung BioLogics, the biopharmaceutical arm of Samsung Group, violated accounting rules in 2015 by inflating the value of an affiliate group, South Korea's watchdog said on Wednesday.
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.